Total Funding
46
79
Total FundingGrant raised
Growth Score
4 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
70306
NysnoBio helps patients with medical conditions develop the Parkin protein's therapeutic potential.
David Giannini: Executive ChairmanPast Role: CirrusWorks, Founder & CEO- Vit Vasista: Chief Financial OfficerPast Role: REGENXBIO, EVP & CFO & Treasurer
About the Company
NysnoBio was the first to discover the Parkin gene, which has been related to Parkinson's disease. They were the first to show Parkin is an E3 ubiquitin ligase, the first to publish a crystal structure proving essential parts of enzymology, the first to use AAV in gene therapy, and in clinical neuroimaging, ensuring decisive outcomes in the
clinic.
